Cullinan Therapeutics, Inc. CGEM
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Cullinan Therapeutics, Inc. (CGEM) is a healthcare company listed in the US with a market value of about $667M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -24%.
About Cullinan Therapeutics
Cullinan Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 1 of the last 6 years in our data. Its share count rose by 39% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $19M | $0 |
| Net income | -$220M | -$167M | -$153M | $111M | -$66M | -$52M |
| Free cash flow | -$176M | -$145M | -$134M | -$128M | -$43M | -$30M |
| EPS (diluted) | $-3.39 | — | $-3.69 | $2.38 | $-1.52 | $-2.60 |
| Net margin | — | — | — | — | -346.1% | — |
| ROIC | -58.7% | -26.3% | -38.3% | 19.3% | -15.9% | -23.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $34.27, 233% above the current price; targets range from $27.00 to $44.00; the consensus rating is “Strong buy”; expected EPS is $-3.01 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Cullinan Therapeutics pay a dividend?
Not currently.
Is Cullinan Therapeutics a good stock to buy?
We do not give buy or sell advice. Cullinan Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.